retatrutide ly3437943 phase 2 trial obesity nejm 2023 Original Article: Triple–Hormone-Receptor Agonist for — A https://t.co/jNL1GNnHPT #ADA23 Retatrutide Phase 3: 28.7% Weight

Not for Diagnostic or Therapeutic Use

While originally developed to treat Type 2 diabetes, the medications have become widely used for weight loss

Nat Meth 10:1922 Matheis K, Laurie D, Andriamandroso C, Arber N, Badimon L, Benain X, Bendjama K, Clavier I, Colman P, Firat H, Goepfert J, Hall S, Joos T, Kraus S, Kretschmer A, Merz M, Padro T, Planatscher H, Rossi A, Schneiderhan-Marra N, Schuppe-Koistinen I, Thomann P, Vidal J-M, Molac B (2011) A generic operational strategy to qualify translational safety biomarkers

For now, it might be best to combine modern therapies with healthy lifestyle choices that have stood the test of time.

Faites de votre grossesse et de votre accouchement une exprience rayonnante

J., Clark, G